A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas - Wikidata - awgldk - TriplyDB

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

http://www.wikidata.org/entity/Q36611857

about

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin Updates of mTOR inhibitors Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy Targeting the mTOR signaling network for cancer therapy The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors Medical treatment for gastro-entero-pancreatic neuroendocrine tumours From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors Targeting the mTOR signaling pathway in neuroendocrine tumors PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors Neuroendocrine tumors of the gastro-entero-pancreatic system PI3K/PTEN signaling in angiogenesis and tumorigenesis Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.A phase I study of temsirolimus and metformin in advanced solid tumours.Enhancing mTOR-targeted cancer therapy.Progress in the treatment of neuroendocrine tumors.Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.Personalising pancreas cancer treatment: When tissue is the issue.Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies Rapamycin selectively reduces the association of transcripts containing complex 5' UTRs with ribosomes in C4-2B prostate cancer cells.New treatment options for patients with advanced neuroendocrine tumors.Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis Gastric neuroendocrine tumours.Therapy for metastatic pancreatic neuroendocrine tumors.Signaling mechanisms in neuroendocrine tumors as targets for therapy.Practical management and treatment of pancreatic neuroendocrine tumors.Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer.Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.Management options in triple-negative breast cancer Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.Targeted therapy in advanced well-differentiated neuroendocrine tumors.

P2860

Q21198871-A28D58D6-2357-4F39-99F2-63EE3E991766 Q21296729-F00C6DD3-9FD0-432B-ACB6-59BFA5D41916 Q24607170-13B2F86C-CB18-4F49-B9D6-0A785911A1E5 Q24628724-80178250-2618-462A-9F8A-D259FEAA7582 Q24658334-668EE2CD-FD33-44D9-91C1-B8C8562954DE Q26740374-2772E63C-BB40-4FEA-AD56-8D35C7D7EA9B Q26751659-39CB9F49-F962-49CF-8D47-E1DA538DCD77 Q26822011-557CDA3F-A311-45DD-BD28-F0D7C88FE558 Q26823873-D18EF527-4322-4497-B909-15FFC0D0EBE4 Q26852089-36339818-749C-4DFA-BD6E-9E05B755C0C0 Q26862544-E69299F2-7963-42A0-8A6C-16C377781196 Q28071388-1346B5FA-76A3-4995-B40F-3C76627C3E24 Q28290833-27128D77-775C-4386-80CB-5E25B499C898 Q28294432-277E9955-2ECA-4302-AD43-0FEB449D8317 Q28383083-9911CE80-FC03-43FC-BFD7-0D3D25DE806D Q33345588-33360CB6-BB8C-473F-9602-77DBF0215B3C Q33383550-CA514B12-F7ED-46DE-94AD-9BE1F1BA1306 Q33392468-14DDFD15-90D3-4374-B54E-EC6EA09C7BA2 Q33604979-18A47088-9795-42E9-9C74-947120BD3486 Q33643643-0EBE5C0A-CFF9-4D71-B636-CD6A838557D5 Q33700134-93873BB2-6369-4449-A3E9-DD7E257F8278 Q33728406-B9143D49-CDA5-498F-B01D-403719FE306A Q33737587-2650FCC3-D427-47A4-B1B0-2B6402134030 Q33782024-4DE3DBA4-7EEF-4F6D-BB88-049C9D1C725C Q33801384-92359CF0-CCA0-46BE-9A27-081D3D32508B Q33840177-6032DE21-6286-4EC4-A788-602C9EC6750A Q34033097-C95C7B1E-8D5D-4EE9-9035-C5F3D9E32951 Q34173336-B00D3845-171B-4DA3-91CD-4D55E0953870 Q34272887-BA49A137-C217-4D7A-8235-DF84063A2C41 Q34306680-228BBB78-E833-4C3D-BCD4-6C3C33C9A4E3 Q34357869-D9F57E17-46FD-4229-8B4B-6BC316AC873E Q34447484-145CB9FE-9F9E-4CDA-85A4-104F4C329DDC Q34573600-D0D3DB57-A8FB-408D-A7CF-11B308867D07 Q34660064-415195C8-32D9-4094-AF36-D5654A69F2F3 Q34887795-4EC9D328-F3BA-42F0-A253-495387087AF6 Q35006620-0C3A6E87-858A-4661-8C6A-F6FE10FB9117 Q35155460-44762197-986A-4C31-A7A3-8E5F69F72036 Q35371197-92E7AF19-3BD6-4CD6-B11E-9CD2E0C5CA5F Q35563828-991C3C4E-9597-4683-8A9E-CCEF61239F89 Q35584497-616F6E96-D7CF-444E-9F0D-41D66C590570

P2860

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

http://www.wikidata.org/entity/Q36611857

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

A phase II clinical and pharma ...... nced neuroendocrine carcinomas

@ast

A phase II clinical and pharma ...... nced neuroendocrine carcinomas

@en

type

label

A phase II clinical and pharma ...... nced neuroendocrine carcinomas

@ast

A phase II clinical and pharma ...... nced neuroendocrine carcinomas

@en

prefLabel

A phase II clinical and pharma ...... nced neuroendocrine carcinomas

@ast

A phase II clinical and pharma ...... nced neuroendocrine carcinomas

@en

P1433

Q36611857-204A2FAE-1647-4389-89A6-2D6BE4626554

P1476

Q36611857-3E4F1078-ECFA-4F6B-8C26-7B31BB232332

P2093

Q36611857-11C420B4-44F9-4EA3-B1D8-4FC6D996F642

Q36611857-31DF0CDC-0895-478E-AC86-C532C6E7EB14

Q36611857-461BDBE0-B232-45FD-8A0A-AE6032C10DA1

Q36611857-5C0BAC3F-47A3-4B5B-BC56-1C083E091921

Q36611857-696CBF58-1B24-4F07-8EC2-6CE24E2A091E

Q36611857-6C716CA1-DBFA-446E-A7B5-C9263424C806

Q36611857-6C871221-AA10-4617-9C3E-5A583090E6D7

Q36611857-7271DC90-46DA-4C60-934C-42BF6B1D0339

Q36611857-7D158F4D-A303-452A-8F7D-4379B72CE583

Q36611857-863FA18B-CEF6-4E63-ABC0-8AADE6164D27

P2860

Q36611857-1DA10F09-21BA-43E6-84AD-67C987F71612

Q36611857-575E0B97-175F-4B11-82BA-C2B22BC2D986

Q36611857-577914B2-8F0A-412C-B6EE-F185F1EC66CC

Q36611857-71C41FCD-9E8D-4D2F-9E97-2CDFCDD9D992

Q36611857-80F62F00-9E49-48D3-BA8E-7E93904664FB

Q36611857-84315F9F-727A-4F2D-B085-7FAE21D89EE1

Q36611857-8E485F65-6DDA-4902-A429-D9E59D514158

Q36611857-9C7DF3D6-9DBE-4C05-9B1B-498CFEE20FF7

Q36611857-A136875F-47FB-4D2A-8451-00B1561B448E

Q36611857-B25CFFD7-F0D9-4223-8292-CA47EDACC87F

P2888

Q36611857-69E0C273-6AB2-46D6-A984-84A676532C17

P304

Q36611857-23EB41B5-E010-4177-B192-633DBDB70F21

P31

Q36611857-E04F5FDD-0182-4240-A7EA-A14D68E46B2E

P356

Q36611857-218057E3-02E4-4943-954F-980C187BFF0D

P407

Q36611857-D57FA8A5-DE9E-47CA-848C-AA8A19B07F51

P433

Q36611857-45AE45C3-24FF-4C08-B831-BD8B61A7BD5A

P478

Q36611857-AAADFF92-9C8D-4606-A309-D05AE9B9D7A1

P50

Q36611857-4EFABBCF-594B-4597-9C02-DDA249B81290

Q36611857-AE3E6ECE-A1C8-4CCB-B5D2-FDEF9A7CE426

P577

Q36611857-2E3D955C-DB84-40E9-A37F-D722C9E19B7B

P5875

Q36611857-7495574F-3B9F-4ED4-9170-85E22743A787

P698

Q36611857-4E4EE227-E39A-4439-A00B-09876247F1D1

P932

Q36611857-219F27CA-B898-49A4-9264-40D6750362A6

P356

P1433

British Journal of Cancer

P1476

A phase II clinical and pharma ...... nced neuroendocrine carcinomas

@en

P2093

A Oza

http://www.w3.org/2001/XMLSchema#string

D Arboine

http://www.w3.org/2001/XMLSchema#string

D Birle

http://www.w3.org/2001/XMLSchema#string

D Singh

http://www.w3.org/2001/XMLSchema#string

G Goss

http://www.w3.org/2001/XMLSchema#string

G R Pond

http://www.w3.org/2001/XMLSchema#string

H Hirte

http://www.w3.org/2001/XMLSchema#string

I Duran

http://www.w3.org/2001/XMLSchema#string

J Dancey

http://www.w3.org/2001/XMLSchema#string

J Ho

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.

mTOR-targeted therapy of cancer with rapamycin derivatives.

Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.

Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.

P2888

P304

1148-1154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6603419

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

Ming-Sound Tsao

P577

2006-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6764577

http://www.w3.org/2001/XMLSchema#string

P698

17031397

http://www.w3.org/2001/XMLSchema#string

P932

2360568

http://www.w3.org/2001/XMLSchema#string